114 related articles for article (PubMed ID: 11031998)
1. [Sphingolipid activator protein deficiency].
Suzuki Y
Ryoikibetsu Shokogun Shirizu; 2000; (29 Pt 4):471-4. PubMed ID: 11031998
[No Abstract] [Full Text] [Related]
2. [Disorders of sphingolipid activator proteins].
Suzuki Y
Nihon Rinsho; 1995 Dec; 53(12):3025-7. PubMed ID: 8577053
[TBL] [Abstract][Full Text] [Related]
3. [Sphingolipid activator protein deficiency].
Inui K
Tanpakushitsu Kakusan Koso; 1988 Apr; 33(5):756-9. PubMed ID: 3270890
[No Abstract] [Full Text] [Related]
4. [Saposin B deficiency].
Kotani Y; Sano A
Ryoikibetsu Shokogun Shirizu; 1998; (19 Pt 2):417-9. PubMed ID: 9645097
[No Abstract] [Full Text] [Related]
5. Sphingolipid activator proteins.
Suzuki K
Essays Biochem; 1995; 29():25-37. PubMed ID: 9189712
[No Abstract] [Full Text] [Related]
6. Synopsis: gangliosidoses.
Schwab ME; Vassella F
Neuropediatrics; 1984 Sep; 15 Suppl():107-9. PubMed ID: 6100793
[TBL] [Abstract][Full Text] [Related]
7. Mutation of the GM2 activator protein in a feline model of GM2 gangliosidosis.
Martin DR; Cox NR; Morrison NE; Kennamer DM; Peck SL; Dodson AN; Gentry AS; Griffin B; Rolsma MD; Baker HJ
Acta Neuropathol; 2005 Nov; 110(5):443-50. PubMed ID: 16200419
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of novel NBD-GM1 and NBD-GM2 for the transfer activity of GM2-activator protein by a FRET-based assay system.
Schwarzmann G; Wendeler M; Sandhoff K
Glycobiology; 2005 Dec; 15(12):1302-11. PubMed ID: 16079415
[TBL] [Abstract][Full Text] [Related]
9. Activator proteins and topology of lysosomal sphingolipid catabolism.
Fürst W; Sandhoff K
Biochim Biophys Acta; 1992 Jun; 1126(1):1-16. PubMed ID: 1606169
[TBL] [Abstract][Full Text] [Related]
10. [GM2 activator protein deficiency (AB variant form of GM2 gangliosidosis)].
Kondoh K; Sano A
Ryoikibetsu Shokogun Shirizu; 1998; (19 Pt 2):411-3. PubMed ID: 9645095
[No Abstract] [Full Text] [Related]
11. Sphingolipid metabolism. Sphingoid analogs, sphingolipid activator proteins, and the pathology of the cell.
Sandhoff K; Kolter T; Van Echten-Deckert G
Ann N Y Acad Sci; 1998 Jun; 845():139-51. PubMed ID: 9668348
[TBL] [Abstract][Full Text] [Related]
12. Quantification of mRNAs encoding proteins of the glycosphingolipid catabolism in mouse models of GM2 gangliosidoses and sphingolipid activator protein precursor (prosaposin) deficiency.
Potratz A; Hüttler S; Bierfreund U; Proia RL; Suzuki K; Sandhoff K
Biochim Biophys Acta; 2000 Nov; 1502(3):391-7. PubMed ID: 11068181
[TBL] [Abstract][Full Text] [Related]
13. Assay of ganglioside GM2-N-acetyl-beta-D-galactosaminidase activity in human fibroblasts employing the natural activator protein--diagnosis of variant forms of GM2 gangliosidosis.
Erzberger A; Conzelmann E; Sandhoff K
Clin Chim Acta; 1980 Dec; 108(3):361-8. PubMed ID: 6781795
[TBL] [Abstract][Full Text] [Related]
14. [Lysosomal storage diseases].
Suzuki Y
Tanpakushitsu Kakusan Koso; 1988 Apr; 33(5):682-5. PubMed ID: 3152089
[No Abstract] [Full Text] [Related]
15. Rare Variant of GM2 Gangliosidosis through Activator-Protein Deficiency.
Brackmann F; Kehrer C; Kustermann W; Böhringer J; Krägeloh-Mann I; Trollmann R
Neuropediatrics; 2017 Apr; 48(2):127-130. PubMed ID: 28192816
[TBL] [Abstract][Full Text] [Related]
16. Mutation in saposin D domain of sphingolipid activator protein gene causes urinary system defects and cerebellar Purkinje cell degeneration with accumulation of hydroxy fatty acid-containing ceramide in mouse.
Matsuda J; Kido M; Tadano-Aritomi K; Ishizuka I; Tominaga K; Toida K; Takeda E; Suzuki K; Kuroda Y
Hum Mol Genet; 2004 Nov; 13(21):2709-23. PubMed ID: 15345707
[TBL] [Abstract][Full Text] [Related]
17. [GM2 ganglioside activator protein deficiency].
Inui K
Ryoikibetsu Shokogun Shirizu; 1998; (19 Pt 2):400-2. PubMed ID: 9645092
[No Abstract] [Full Text] [Related]
18. Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids.
Kolter T; Sandhoff K
Annu Rev Cell Dev Biol; 2005; 21():81-103. PubMed ID: 16212488
[TBL] [Abstract][Full Text] [Related]
19. [Saposins and sphingolipid metabolisms].
Hiraiwa M; Kishimoto Y
Seikagaku; 1996 Jun; 68(6):464-74. PubMed ID: 8741292
[No Abstract] [Full Text] [Related]
20. Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids.
Fujita N; Suzuki K; Vanier MT; Popko B; Maeda N; Klein A; Henseler M; Sandhoff K; Nakayasu H; Suzuki K
Hum Mol Genet; 1996 Jun; 5(6):711-25. PubMed ID: 8776585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
